The class I selective HDAC inhibitor romidepsin (FK228) is effective in reducing ovarian cancer cell proliferation at nanomolar concentrations [44], and multiple HDAC inhibitors are in ongoing cancer clinical trials [45],[46]. Here, HDAC9 is linked to cancer.